...we verified the effect of CCL5 on survival and response to treatment in another cohort that received immunotherapy....The result of Tumor Immune Dysfunction and Exclusion (TIDE) demonstrated that CCL5 was a potential biomarker to predict response to ICB for SCLC, which is correspondent with the result in verified cohort...patients received the anti-PD-L1 antibody durvalumab and poly(adp-ribose) polymerase (PARP) inhibitor Olaparib (Figure 7E). The expression of CCL5 was statistically different between responders and non-responders (Figure 7F). CCL5 was highly expressed in the responders group. Receiver operating characteristic (ROC) curve also reveals that CCL5 is a good marker to predict the result of immunotherapy (AUC = 0.904) (Figure 7G).